Comparing the current results to its competitors, Humacyte Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 10.32 %, recorded in the same quarter.
Humacyte Inc 's Comment on Competition and Industry Peers
The company anticipates its ATEVs will compete with patients' own blood vessels and various marketed products, including conventional synthetic grafts, xenografts, and allografts. Key competitive factors include efficacy, safety, convenience, pricing, and reimbursement. Conventional synthetic grafts made of ePTFE or Dacron are currently marketed by Bard Peripheral Vascular, Inc., W.L. Gore & Associates, Inc., Terumo Medical Systems, and Atrium (Maquet Getinge Group). Xenograft products such as Artegraft® and Procol® are processed animal-derived vessels, while allografts are available but not widely used. Additionally, companies with preclinical and early clinical-stage research programs developing potentially competing products include NovaHep AB, Xeltis AG, Hancock Jaffe, and Vascudyne Inc. Emerging technologies like bioabsorbable polymeric implants and electrospun or 3D printed tubular conduits may also present competition. Competitors may obtain FDA or other marketing approvals more rapidly, potentially establishing strong market positions before the company enters the market.
November 21, 2024
Revolutionary Advances in Vascular Repair: Humacyte s ATEV and BVP Programs Presented in JAMA SurgeryIn a landmark publication, Humacyte Inc. announced its innovative Acellular Tissue Engineered Vessel (ATEV) has demonstrated compelling benefits in repairing arterial injuries, as published in the prestigious JAMA Surgery. This development marks a significant breakthrough in both civilian and military healthcare, opening new vistas for treatment paradigms. Clinical Breakthroughs in Arterial Injury Repair The recently published studies focus on the promise of the ATEV in treating arterial injuries, which are often life-threatening and challenging to manage due to high rates of infection and complications. The...
November 20, 2024
Humacyte Inc.: Navigating Legal Challenges and Stagnant Revenue Growth in the Biopharmaceutical Landscape In recent developments concerning Humacyte Inc. a class action lawsuit has been filed against the company in the United States District Court for the Middle District of North Carolina. This legal action represents potential challenges for the biopharmaceutical company, which is simultaneously contending with underwhelming financial performance compared to industry peers. This article explores the legal and financial issues facing Humacyte, analyzing their implications for the company s future operations and performance in the highly competitive market of regenerative medicine. The Class Action Lawsuit Ag...
November 19, 2024
Humacyte, Inc. (NASDAQ: HUMA) has found itself at the center of significant legal and operational challenges following the filing of a shareholder class action lawsuit. The lawsuit has brought to light critical issues related to manufacturing practices and regulatory delays that, when combined with the company s underperforming financial metrics, underscore the precarious situation Humacyte faces in a competitive biopharmaceutical landscape. This article examines the allegations, financial performance, and the potential implications for Humacyte and its stakeholders. Overview of the Class Action Lawsuit 1. Allegations Against Humacyte: - The shareholder lawsuit alleges that Humacyte made materially false...
October 8, 2024
Advancements in Vascular Access for Hemodialysis: Humacyte’s Bioengineered Vessels in the Spotlight at ASN Kidney Week 2024 In the continuing quest to enhance medical outcomes for patients with end-stage renal disease (ESRD), particularly those requiring hemodialysis, innovation in biotechnology displays the potential to transform standard practices. A groundbreaking development in the form of bioengineered human tissues offers promise for the future of vascular access management. Humacyte, Inc. a leader in biotechnology centered on the commercial scale production of universally implantable human tissues, has showcased pioneering advancements with its acellular tissue engineered vessel (ATEV). In a signifi...
July 31, 2024
Breakthrough in Hemodialysis: Humacyte s Acellular Tissue Engineered Vessel Outperforms Standard Fistula in Phase 3 TrialIn a significant advancement in the realm of hemodialysis access, Humacyte has unveiled the promising results from its V007 Phase 3 clinical trial, establishing its Acellular Tissue Engineered Vessel (ATEV) as a superior alternative compared to the traditional autogenous fistula. This landmark study is poised to revolutionize patient care for individuals requiring renal replacement therapy, given the critical importance of vascular access in hemodialysis efficacy and patient outcomes.The trial, designed to assess the effectiveness of ATEV in creating arteriovenous access for hemodialysis,...
June 17, 2024
The Centers for Medicare and Medicaid Services (CMS) recently announced the issuance of four distinct ICD-10-PCS codes, effective from October 1, 2024. These codes are specifically designated for the replacement of arteries in the upper and lower extremities using Humacytes Human Acellular Vessel (HAV). This development holds significant implications for the field of drug discovery and healthcare, as it paves the way for enhanced reimbursement accuracy and monitoring of treatment outcomes.ICD-10-PCS Codes and Their Significance:The CMS has bestowed four unique ICD-10-PCS codes solely for the replacement of arteries in the upper and lower extremities with Humacytes HAV. The ICD-10-PCS is a standardized coding...
December 12, 2023
Humacyte Submits BLA to U.S. FDA for Human Acellular Vessel (HAV) - A Revolutionary Treatment for Vascular Trauma
BLA supported by results from Phase 2/3 clinical trial and outcomes of real-world use of the HAV under a humanitarian aid program to treat wartime trauma injuries in Ukraine
In a groundbreaking development, biotechnology company Humacyte has recently submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the approval of their innovative treatment called Human Acellular Vessel (HAV). This revolutionary medical technology has the potential to transform the way vascular trauma injuries are treated, providing hope for co...
Aura Biosciences Inc is a biotechnology company that focuses on developing and commercializing therapies to treat cancer. They utilize their proprietary Tumor Paint technology to selectively deliver light-activated drugs directly to tumors, aiming to improve treatment outcomes and minimize side effects.
Organogenesis Holdings Inc is a regenerative medicine company that specializes in the development and commercialization of advanced wound care and surgical biologic products. Their business model revolves around leveraging their expertise in tissue engineering and biotherapeutics to create innovative products aimed at treating various chronic and acute conditions. Through strategic partnerships, they distribute their products globally to healthcare professionals and patients in need, focusing on improving patient outcomes and quality of life.
Ocugen Inc's business model is focused on the development and commercialization of innovative gene therapies to treat rare and underserved ocular diseases, with a particular emphasis on underserved patient populations. They aim to leverage their expertise in gene therapy and partnerships to advance novel treatments and bring them to market, ultimately improving the lives of patients in need.
Mesoblast Ltd is a biotechnology company that operates on a business model focused on the development and commercialization of proprietary cell-based regenerative medicines. They aim to transform the treatment of various degenerative diseases by utilizing their patented technology and strategic partnerships with pharmaceutical companies.
Organicell Regenerative Medicine Inc's business model focuses on developing and commercializing regenerative therapies derived from perinatal tissues, such as placental tissues and umbilical cord blood.
Sources:
Humacyte Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Humacyte Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
